Swedish Orphan Biovitrum AB (publ) : The board of directors exercises authorisation for repurchase of shares for the purpose of securing the company's commitments under the incentive programme
(Thomson Reuters ONE) -
The annual general meeting of Swedish Orphan Biovitrum AB (publ) on 30 June
2015 resolved - for the purpose of ensuring that the company can fulfil its
commitments under the long-term incentive programme resolved by the annual
general meeting - on a directed share issue of no more than 1,036,856
redeemable- and convertible class C shares.
The general meeting also resolved to authorise the board of directors to resolve
on the repurchase of all issued class C shares by an offer directed to all
holders of class C shares. Repurchase under this authorisation may be made on
one or several occasions until the annual general meeting in 2016 and at a price
to no less than 100 per cent and no more than 105 per cent of the quotient value
of the share (approximately SEK 0.55).
The board of directors has resolved to exercise the repurchase authorisation for
the said purpose by repurchasing of all issued class C shares against payment of
100 per cent of the quotient value of the share, corresponding to approximately
SEK 0.55 per share. Repurchase of the class C shares may be effected during the
period 11 September - 27 September 2015.
The company currently holds 2,763,768 own common shares and 396,180 own class C
shares. Subsequently to the effected repurchase of class C shares above, the
number of own class C shares will amount to 1,433,036.
The class C shares will, following the repurchase, be converted to common shares
in the number that is required to ensure delivery under the incentive programme.
---
About Sobi
Sobi is an international specialty healthcare company dedicated to rare
diseases. Our mission is to develop and deliver innovative therapies and
services to improve the lives of patients. The product portfolio is primarily
focused on Haemophilia, Inflammation and Genetic diseases. We also market a
portfolio of specialty and rare disease products for partner companies across
Europe, the Middle East, North Africa and Russia. Sobi is a pioneer in
biotechnology with world-class capabilities in protein biochemistry and
biologics manufacturing. In 2014, Sobi had total revenues of SEK 2.6 billion
(USD 380 M) and about 600 employees. The share (STO: SOBI) is listed on NASDAQ
OMX Stockholm. More information is available at www.sobi.com.
For more information please contact
Media relations Investor relations
Oskar Bosson, Head of Jörgen Winroth, Vice President, Head of Investor
Communications Relations
T: +46 70 410 71 80 T: +1 347-224-0819, +1 212-579-0506, +46 8 697 2135
oskar.bosson(at)sobi.com jorgen.winroth(at)sobi.com
The information was released for public distribution on 11 September 2015 at
08:30 CET.
034e_Repurchase of shares:
http://hugin.info/134557/R/1951205/709530.pdf
This announcement is distributed by GlobeNewswire on behalf of
GlobeNewswire clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Swedish Orphan Biovitrum AB (publ) via GlobeNewswire
[HUG#1951205]
Unternehmensinformation / Kurzprofil:
Datum: 11.09.2015 - 08:31 Uhr
Sprache: Deutsch
News-ID 419453
Anzahl Zeichen: 3716
contact information:
Town:
Stockholm
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 159 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Swedish Orphan Biovitrum AB (publ) : The board of directors exercises authorisation for repurchase of shares for the purpose of securing the company's commitments under the incentive programme"
steht unter der journalistisch-redaktionellen Verantwortung von
Swedish Orphan Biovitrum AB (publ) (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
